Therapeutic Implications of Targeting AKT Signaling in Melanoma

Figure 9

Cotargeting Akt3 and ^V600EB-Raf inhibits melanoma cell proliferation in vitro. Two hundred picomoles of siRNA targeting Akt3 and increasing (3, 6, and 12 picomoles) amounts of siRNA inhibiting ^V600EB-Raf were introduced alone or in combination into UACC 903 melanoma cell line by Amaxa transfection and effect on anchorage independent growth ability measured using MTS assay. The data shows a dose-dependent inhibition of cell viability when Akt3 and ^V600EB-Raf were inhibited. However, maximal effect was observed only when Akt3 and ^V600EB-Raf targeted together, indicating the necessity of inhibiting multiple signaling cascades [46, 151].